



RECEIVED

JUN 28 2002

TECH CENTER 1600/2900 Dkt. #651

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : DONG, et al.
U.S. Serial No.: 09/829,073
Filed : April 9, 2001 Examiner: COOK, LISA V
For : HUMAN ZONA PELLUCIDA PROTEIN 3 AND USES
THEREOF

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

June 21, 2002

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

**COMMUNICATION IN RESPONSE TO May 22, 2002 NOTICE TO COMPLY
WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**


This Communication is submitted in response to the May 22, 2002 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (**Exhibit A**). The deadline for filing this Communication and the attached items is June 22, 2002. Therefore, this Communication is being timely filed.

Applicants hereby attach a copy of the Sequence Listing in computer-readable form as required by 37 C.F.R. 1.821(e) (**Exhibit C** and a floppy disk). Applicants hereby state in the attached Statement to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (**Exhibit B**) that the content of the sequence listing information recorded in computer-readable form is identical to the written sequence listing and includes

16443
7/2/02
Box Sequence

Applicants : DONG, et al.
 U.S. Serial No.: 09/829,073
 Filed : April 9, 2001
 Date : June 21, 2002
 Page : 2

no new matter, as required by 37 C.F.R. 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).



The attached sequence listing (**Exhibit C** and the **floppy disk**) was created with PatentIn Version 3.1 Software, and checked with Checker Version 3.1 Software, both Softwares are up-to-date versions of the USPTO's authoring software for sequence listings required for biotechnical applications disclosing DNA or protein sequences.

Applicants believe that the application now is in compliance of all sequence listing requirements and respectfully requests that the Examiner to whom this application is assigned render substantive Office Action.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan


Albert Wai-Kit Chan
 Registration No. 36,479
 Attorney for Applicants
 Law Offices of
 Albert Wai-Kit Chan, LLC
 World Plaza, Suite 604
 141-07 20th Avenue
 Whitestone, New York 11357
 Tel: (718) 357-8836
 Fax: (718) 357-8615
 e-mail: kitchanlaw@aol.com

Applicants : DONG, et al.
U.S. Serial No.: 09/829,073
Filed : April 9, 2001
Date : June 21, 2002
Page : 3

I hereby certify that this paper is being deposited this date with the U.S. Postal Service with sufficient postage for first class mail in an envelope addressed to:

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Chun Tam 6/21/02
Mr. Chun Tam Date



TECH CENTER 1600/2900

JUN 28 2002

RECEIVED

Notice to Comply

Application No.

09/829,073

Examiner

Lisa V. Daniels-Cook

Applicant(s)

Dong, Ke-Wen et al.

Art Unit

1641

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: There are no amino acid sequences and identifiers (SEQ ID NO's) to define recombinant reduced valency CBLs for mutation at specified amino acid positions.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support


Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : DONG, et al.
U.S. Serial No.: 09/829,073
Filed : April 9, 2001 Examiner: COOK, LISA V
For : HUMAN ZONA PELLUCIDA PROTEIN 3 AND USES
THEREOF



Law Offices of Albert Wai-kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

June 21, 2002

RECEIVED

JUN 28 2002

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

TECH CENTER 1600/2900


Sir:

STATEMENT TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

I hereby state that the content of the sequence listing information recorded herewith in computer-readable form is identical to the attached written sequence listing (as disclosed in the above-identified patent application) and includes no new matter, as required by 37 C.F.R. 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Qing He

Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 357-8836
Fax: (718) 357-8615